Background: Inotropes and vasopressors are frequently administered to critically ill patients in order to improve haemodynamic function and restore adequate organ perfusion. However, some studies have suggested a possible association between inotrope administration and increased mortality. We therefore performed a meta-analysis of randomized trials published in the last 20 yr to investigate the effect of these drugs on mortality. Methods: BioMedCentral, PubMed, Embase and the Cochrane Central Register were searched (all updated April 8th, 2015). Inclusion criteria were: random allocation to treatment, at least one group receiving an inotropic or vasopressor drug compared with at least one group receiving a non-inotropic/vasopressor treatment, study published after 1st January 1994, and systemic drug administration. Exclusion criteria were overlapping populations, studies published as abstract only, crossover studies, paediatric studies and lack of data on mortality. Results: A total of 28 280 patients from 177 trials were included. Overall, pooled estimates showed no difference in mortality between the group receiving inotropes/vasopressors and the control group [4255/14 036 (31.7%) vs 4277/14 244 (31.8%), risk ratio=0.98 (0.96-1.01), P for effect=0.23, P for heterogeneity=0.30, I
myocardial ischaemia, and metabolic alterations. 3 Most of the routinely used inotropic and vasopressor agents exert their haemodynamic effect through enhancement of the adrenergic pathway. 2 3 Unfortunately, there is growing evidence that excessive adrenergic stimulation is detrimental during critical illness. 4 5 In fact, there is evidence from both randomized [6] [7] [8] and observational trials, 9 10 and also meta-analyses, 11 done in the heart failure setting, that despite improvements in haemodynamic function, inotropic agents might reduce survival. Moreover, some recent observational trials also suggest a possible harmful effect in cardiac surgery.
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However, given the fact that treatment with inotropes/vasopressors is generally reserved in extremis for the most severely ill patients, association with increased mortality could be coincidental, particularly in non-randomized trials.
14 Several clinical trials in a wide range of clinical settings have been performed with controversial results; nevertheless, few large randomized studies exist. We therefore performed a meta-analysis of randomized clinical trials (RCT) evaluating inotrope/vasopressor therapy in adults to elucidate the effect of these drugs on survival.
Methods

Search strategy
We developed a search strategy aimed to include any RCT performed in adults with at least one group treated with an inotropic or vasopressor drug in any clinical setting (Search strategy for PubMed provided as Supplementary data Appendix). Pertinent studies were independently searched (all searches updated January 31st, 2014) in PubMed, BioMedCentral, Embase, and the Cochrane Central Register of clinical trials, by two trained investigators. In addition, references of retrieved articles and pertinent reviews were scanned to identify further studies
Study selection
References were first independently examined at a title/abstract level by two investigators, with divergences resolved by consensus, and then, if potentially pertinent, retrieved as complete articles. Inclusion criteria were: random allocation to treatment, at least one group receiving an inotropic or vasopressor drug compared with at least one group receiving a non-inotropic/vasopressor treatment (including placebo or best available treatment), study published after 1st January 1994, and systemic drug administration. We decided to include in our study only drugs that are routinely administered and are available in USA or in Europe (Table 1) . Definition of a drug as an inotrope or a vasopressor is described in Supplementary data Table S1 . The exclusion criteria were: overlapping populations (in this case we referred to the first article published while retrieved data from the article with the longest follow-up available), studies published as abstract only, crossover studies, paediatric populations, and lack of data on mortality. No language restriction was applied. Two investigators independently assessed compliance to selection criteria and selected studies for the final analysis, with divergences resolved by consensus.
Data abstraction and analysis
Data regarding number of patients, treatment type, clinical setting, follow-up and mortality were independently abstracted by four trained investigators. Corresponding authors of retrieved articles reporting no data on mortality were contacted by email to obtain missing data. The primary endpoint of the present study was mortality at the longest follow-up available.
Computations were performed with RevMan (Review Manager version 5.2, The Nordic Cochrane Center, The Cochrane Collaboration, Copenaghen, 2012) and Stata (Stata Statistical Software: release 13, StataCorp LP, College Station, Texas).
Hypothesis of statistical heterogeneity was tested by means of Cochran Q test, with statistical significance set at the two-tailed 0.10 level, whereas extent of statistical consistency was measured with I 2 , defined as 100% X (Q-df )/Q, where Q is Cochran's heterogeneity statistic and df the degrees of freedom. As the test has low power in a meta-analysis in which studies have small sample size or are few in number, we set statistical significance for hypothesis of heterogeneity at a P value of 0.10. Data on mortality were extrapolated to compute the individual and pooled risk ratio (RR) with pertinent 95% confidence interval (CI), by means of Mantel-Haenszel method and with a fixed-effect model in case of low statistical inconsistency (I 2 ≤25%), or with random-effect model (which better accommodates clinical and statistical variations) in case of moderate or high statistical inconsistency (I 2 >25%). Egger's linear regression test and Begg's adjusted-rank correlation test were performed to assess the presence of publication bias. Quality of included trials was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions.
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In addition to the principal analysis considering all the studies that fulfilled inclusion criteria, we also performed secondary analyses to investigate specific clinical settings and the effect of the different drugs (definitions of medical conditions used for  subgroup analysis are presented in Supplementary data Table S2 ). Moreover, we investigated the effect of the study drugs at different follow-up. For studies investigating more than two comparators (e.g. dobutamine vs levosimendan vs placebo), the different groups were either aggregated as a single group or analysed separately, depending on the specific analysis performed.
Additional sensitivity analyses performed included studies randomizing more than 100 patients, studies judged to carry a low risk of bias, studies with prophylactic vs therapeutic drug administration, and studies with placebo as comparator. We sequentially removed each study and re-analysed the remaining dataset ( producing a new analysis for each study removed). We also sequentially removed simultaneously all the studies performed in a specific setting, and repeated the analysis simultaneously removing all the studies performed with a specific agent. In addition, we computed both the pooled odds ratio (OR) and risk difference (RD) to assess the effect of the analysis method on our result. Finally we carried out a metaregression model to assess the effect of duration of treatment, mortality in the control group and age on the global estimate.
Statistical significance was set at the two-tailed 0.05 level for hypothesis testing of effect, and 0.10 for hypothesis testing of heterogeneity. P values unadjusted for multiplicity are reported throughout.
The present systematic review was conducted in keeping with Preferred Reporting Items for Systematic Reviews and Metaanalysis.
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Results
Database searches and snowballing yielded a total of 16 237 titles. Excluding 15 530 nonpertinent titles or abstracts, 707 papers were retrieved in complete form and assessed according to selection criteria (Fig. 1) .
Excluded papers are available in the Supplementary data Appendix, together with the reason for exclusion (Supplementary data  Table S3 ). The most common reasons for exclusion were: no outcome data even after contacting the corresponding authors (260 studies), inotropic/vasopressors comparator (103 studies), studies published before 1st January 1994 (31 studies), overlapping populations (30 studies), and paediatric population (20 studies); additional reasons for exclusion are presented in Fig. 1 . A total of 532 articles were excluded; therefore, 175 papers, describing 177 trials, were included in the final analyses ( (Table 3 ). Quality assessment of included trials showed that most of the studies were of moderate quality. A total of 60 studies (33.9%) were judged to carry a low risk of bias, 104 (58.8%) a moderate risk of bias, and 13 (7.3%) a high risk of bias (Supplementary data  Table S5 ).
Quantitative data synthesis
The overall analysis showed that mortality in patients receiving inotropes/vasopressors was not increased when compared with control [4255/14 036 (30.3%) deaths in the treatment group vs 4277/14 244 (30%) deaths in the comparator group, RR=0.98 (0.96-1.01), P for effect=0.23, P for heterogeneity=0.30, I
2 =6%] ( (Table 3) .
No difference between treatments was found when analysing studies randomizing more than 100 patients, studies comparing inotropes/vasopressors with placebo, studies performed in 'conventional' settings, studies carrying a low risk of bias, studies with therapeutical drug administration, and by changing analysis methods. Removing each study, each setting and each agent and reanalysing the remaining data set did not determine major changes in direction or magnitude of statistical findings (Table 3) . No subgroup analysis showed an increased mortality associated to the use of inotropes/vasopressors. Begg test and Egger's test excluded presence of a publication bias (P=0.14 and P=0.81, respectively). Funnel plot is presented as Supplementary data Figure S1 .
Meta-regression analyses did not find a significant effect of disease severity (slope=0.0003, 95% CI −0.001-0.0005, P=0.44; Supplementary data Fig. S2 ), duration of treatment (slope=0.00001, 95% CI −0.00007-0.0001, P=0.77; Supplementary data Fig. S3 ), and age (slope=0.004, 95% CI −0.01-0.001, P=0.13; Supplementary data Fig. S4 ), on our results. Forest plots of the main analysis and sub-group analyses with a statistically significant result are available as supplementary material (Supplementary data Fig. S5-11 ).
Discussion
The most important finding of this study is that, according to published randomized evidence, inotropic and vasoconstrictors have no detrimental effect on survival. This is important for clinicians who routinely use these drugs in critically ill patients to stabilize haemodynamics and might surprise some who are aware that a few RCTs reported a detrimental effect on survival. 6-8 193 Notably, the most relevant of these randomized trials showing a poor outcome in patients receiving inotropic agents (e.g. the PROMISE study 6 and the Xamoterol in Severe Heart Failure study 7 ) were done in the setting of chronic, stable heart failure.
In our study we did not find an increase in mortality in this setting with the use of inotropes; however, several studies on inotrope use in chronic heart failure, such as the above mentioned, were published before 1994 and were therefore excluded in our analysis. In the last 20 yr, the largest studies published in this setting were the Digitalis Investigation Group (DIG) trial (1997), 57 the Vesnarinone Trial (1998) 8 and the ESSENTIALs trials (2009).
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The DIG trial enrolled 6,800 patients and is, to the best of our knowledge, the largest RCT ever performed on an inotrope; it compared digoxin with placebo and found that, although digoxin reduced the rate of hospitalizations, it did not affect all-cause mortality. 57 The Vesnarinone Trial (3,833 patients, the second largest trial on inotropes ever performed) found that vesnarinone (a mild phosphodiesterase inhibitor with several effects on intracellular ion balance) increased mortality in a dose-dependent manner. 8 In the two ESSENTIAL trials 1854 patients were randomized to low-dose oral enoximone or placebo; enoximone treatment did not affect mortality nor improved major clinical outcomes. 122 Of note, all the above mentioned trials evaluated daily oral administration of inotropic agents. Because of the results of these and earlier trials, treatment with inotropes in stable heart failure is currently contraindicated and can be considered only when palliative or bridge therapy is required. 194 195 A possible exception might be intermittent i.v. levosimendan administration in patients with advanced heart failure. In recent meta-analyses levosimendan improved survival in both cardiology and cardiac surgery settings 14 and pulsed levosimendan has been showed to reduce mid-term mortality in advanced heart failure. 196 If we specifically consider acute or decompensated heart failure, the effect of inotropes is less defined. There are some evidences from observational studies that inotropes in general and catecholamines in particular could increase mortality. [7] [8] [9] Moreover, in a meta-regression analysis, Thackray and colleagues 11 found a non-significant increase in mortality associated with Effect of inotropes on mortality | 665 On the other hand, no randomized study has yet demonstrated a clear positive or negative effect of inotropic drugs on survival. In the largest trial, the OPTIME-CHF study, patients with acutely decompensated heart failure were randomized to a 48-h infusion of milrinone or placebo. 49 The investigators found no difference in 60-day mortality rate; however, they found an increase in early adverse events related to arrhythmias or hypotension in the milrinone-treated group. 49 A post-hoc analysis of this trial suggested that milrinone might be harmful in patients with ischaemic heart failure, whereas it could be beneficial in patients with non-ischaemic cardiomyopathy. 197 The authors hypothesized that this effect could be as a result of the accelerated apoptosis, and thus heart failure progression, in the chronically ischaemic, hibernating myocardium, mediated by the adrenergic signaling pathways. 197 198 The recent ROSE trial investigated the effect of dopamine, nesiritide and placebo on renal function in decompensated heart failure patients (360 patients randomized); the authors reported no difference in mortality at 180-days follow-up; however dopamine was used at low-dose (2 µg kg −1 min −1 ) and mortality was not the primary endpoint of the study. 44 Most of the other major trials in the setting of acute or decompensated heart failure evaluated levosimendan, and these trials showed controversial results, with levosimendan having either a beneficial or neutral effect on survival. In our study, that includes the major trials performed on patients with acute heart failure, we found no difference in mortality between patients treated with inotropes and control patients in this particular setting. In cardiac surgery, inotropes are used in 20-90% of patients, depending on the preoperative state, complexity of procedure, patient's response to surgery and physician attitude.
12 13 199 The most common reason to administer inotropes in this setting is to prevent or treat postoperative low-cardiac output syndrome, a complication that increases both morbidity and mortality. 192 Some observational trials reported increased mortality associated with inotropes use in the setting of cardiac surgery 12 13
; however others found no difference in major clinical outcomes between patients who received inotropes and those who did not. 199 We found that inotropes do not seem to increase mortality in cardiac surgery. On the contrary, treatment with inotropic and vasopressor drugs was associated with improved survival. Unfortunately, despite being so widely used in the perioperative period, large, randomized trials focusing on clinically relevant endpoints are lacking. 192 In our systematic review we found no study randomizing patients with severe vasodilatory shock to norepinephrine or no vasopressor therapy. Nonetheless, we found trials investigating the effect of non-catecholaminergic vasopressors (i.e. vasopressin, terlipressin and methylene blue) vs placebo or standard treatment. Because of the possible side-effects of catecholamines, [2] [3] [4] [5] interest in new vasopressors acting through pathways other than the adrenergic pathway has recently developed. 200 Interestingly, we found that treatment with these agents in patients with or at risk for vasoplegia and vasodilatory shock might be associated with a significant increase in survival. It is worth noticing that the recent VASST trial found no difference in mortality between patients with septic shock treated with norepinephrine or vasopressin, 201 while a recent meta-analysis, including also the VASST trial, suggested that vasopressin and terlipressin might reduce mortality in patients with vasodilatory shock. 201 Further researches on the topic are therefore recommended.
If we consider the different drugs, we found that levosimendan is the only drug that significantly improved survival. This result is consistent with a previous meta-analysis.
14 However, despite being a promising and extensively studied agent, levosimendan
has not yet been shown to improve survival in large, multicenter randomized clinical trials. Three additional trials on levosimendan use in the setting of cardiac surgery (HSR-LEVO, NCT00994825 -LICORN, P110138 -LEVO-CTS, NCT02025621) and one in the setting of sepsis (LeoPARDS -ISRCTN12776039) are currently ongoing, and Effect of inotropes on mortality | 667 are expected to better define the role of levosimendan in treatment of critically ill patients. [202] [203] [204] The finding of an improved one-month survival in patients receiving inotrope or vasopressor therapy, should be considered with caution, as only 17% of trials reported one-month mortality and this trend was diluted when including one-yr follow-up data. It is worth noting that although concerns regarding the safety of inotropes have been raised, particularly towards their effect on long-term mortality, unfortunately, only 5.6% of studies reported this information. The need for a systematic report of long-term outcome have been also highlighted by recently published guidelines from the European Society of Anaesthesiology/European Society of Intensive Care Medicine for reporting outcome of trials in perioperative medicine. 205 Finally, we found that inotrope or vasopressor therapy may improve survival when administered prophylactically, a finding which is in contrast with the general agreement that these drugs should be reserved for critically ill patients. Indeed, preemptive haemodynamic optimization (which usually imply administration of inotropes and fluids) seems to improve survival in high-risk surgical patients. 206 On the contrary, it has not shown efficacy in critically ill patients, 193 207 and even the concept of early goal-directed therapy for septic shock, 208 a mainstay of sepsis treatment, has been recently challenged by recent large trials.
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Limitations
Our study has several limitations. First of all, we investigated heterogeneous settings ranging from septic patients to those undergoing cardiac surgery to those suffering from complications of liver cirrhosis such as hepatorenal syndrome. Patients′ followup also varies widely among the different studies. In addition, we investigated the effect of a large number of different drugs, with different mechanisms of actions, indications and side-effects. Nonetheless, all sub-analyses confirmed magnitude and direction of our main results. Another important limitation we have to acknowledge is that it is likely that statistically significant results have been influenced by trials investigating levosimendan, (the only drug associated with a statistically significant survival benefit), which consisted of 27% of all included trials. Therefore, these results should be interpreted with caution. Furthermore, we excluded trials investigating drugs that are not anymore available for prescription, usually because of negative results of the trials. Examples of such agents include vesnarinone, pimobendan, ibopamine and tilargine acetate. A strength of our study is that we included only trials published after 1st January 1994. Even if, as a consequence, several trials were excluded, the most important of which is probably the PROMISE study from 1991, 6 this adds modernity to our meta-analysis. It is likely that, including also the early-1990s trials on inotropes use in chronic stable heart failure, we would have found that inotropes increase mortality in this subset of patients. On the contrary, we are not aware of other large, randomized trials performed in other clinical settings before 1994 that might have importantly influenced our results.
Conclusions
Our study shows that in the overall analyses and in different clinical settings, inotropes and vasopressor use was not associated with an increase in mortality, according to published randomized evidences. On the contrary, vasoactive agents administration in vasodilatory shock and cardiac surgery, and prophylactic administration of vasoactive agents, might improve survival. We also observed a beneficial overall effect of inotropic and vasoconstrictors at one-month follow-up. It is worth noting that we found no randomized study comparing treatment with an inotropic/vasopressor drug and no treatment at all with such medications in critically ill, unstable patients, nor are we aware of any trial with such a design published before 1994 or ongoing. This may reflect the fact that, despite concerns expressed in observational studies, clinicians′ belief is that inotropic/vasopressor drugs improve patients′ survival, when used appropriately. Our study suggests that inotropes are not detrimental per se; as for many other drugs, accurate evaluation of benefits and risks and selection of the correct agent is required in every clinical setting. 
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